Myostatin inhibition gets further PoC for lean mass preservation in obesity

Two recent Phase II studies have established proof of concept that myostatin inhibitors can substantially improve the quality of weight loss, without adding any notable toxicity, when combined with marketed obesity therapies. They also set the bar for the upcoming readout of Lilly’s activin antagonist bimagrumab. 

Scholar Rock Holding Corp. (NASDAQ:SRRK) reported positive data from the Phase II EMBRAZE study of MSTN inhibitor apitegromab that showed after 24 weeks of once-monthly treatment, the combination of apitegromab plus Zepbound tirzepatide from Eli Lilly and Co. (NYSE:LLY) led to a 55% increase in lean mass preservation vs. patients receiving Zepound alone. ...